Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease
NCT ID: NCT00954460
Last Updated: 2021-05-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
APPROVED_FOR_MARKETING
EXPANDED_ACCESS
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase
NCT00478647
Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease
NCT00553631
Multicenter Extension Study of Velaglucerase Alfa in Japanese Patients With Gaucher Disease
NCT01842841
Efficacy and Safety Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher Disease
NCT01685216
A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease
NCT00430625
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
velaglucerase alfa
up to 60 U/kg, every other week via intravenous infusion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The patient is \> 2 years of age
3. The patient has NOT previously experienced an anaphylactic or anaphylactoid reaction to another ERT including imiglucerase
4. Women of child-bearing potential must agree to use a medically acceptable method of contraception at all times during the study; and must have a negative result to a pregnancy test as required throughout their participation in the study. Male patients must use a medically acceptable method of birth control throughout their participation in the study and must report their partner's pregnancy.
5. The patient is sufficiently cooperative to participate in this treatment plan as judged by the Investigator
6. If the patient is naïve or new to treatment, the patient has one or more of the following (in absence of the following criteria, please call the sponsor for treatment justification):
* Gaucher disease-related anemia
* Moderate splenomegaly (2 to 3 cm below the left costal margin), by palpation
* Gaucher disease-related thrombocytopenia
* Gaucher disease-related palpable enlarged liver
3 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shire
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Study Director
Role: STUDY_DIRECTOR
Takeda
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St Joseph's Hospital & Medical Center
Phoenix, Arizona, United States
Tower Hematology Oncology
Beverly Hills, California, United States
Rady's Children's Hospital of San Diego
La Jolla, California, United States
Southern California Permanente Medical Group
Los Angeles, California, United States
The Permanente Medical Group
Sacramento, California, United States
Stanford University Medical Genetics
Stanford, California, United States
Rocky Mountain Cancer Centers
Denver, Colorado, United States
Yale University
New Haven, Connecticut, United States
University Research Foundation for Lysosomal Storage Diseases
Coral Springs, Florida, United States
Gainesville Hematology Oncology Associates
Gainesville, Florida, United States
Adventis Healthcare System dba Florida Hospital
Orlando, Florida, United States
East Lake Oncology
Palm Harbor, Florida, United States
Emory Genetics
Decatur, Georgia, United States
Children's Memorial Hospital
Chicago, Illinois, United States
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
Annapolis Oncology Center
Annapolis, Maryland, United States
Sinai Hospital of Baltimore
Baltimore, Maryland, United States
University of Massachusetts
Shrewsbury, Massachusetts, United States
Children's Hospitals and Clinics of Minnesota
Minneapolis, Minnesota, United States
The University Research Foundation for Lysosomal Storage Diseases
Kansas City, Missouri, United States
St. Joseph's
Paterson, New Jersey, United States
Hemophilia Center of Western New York Incorporated
Buffalo, New York, United States
North Shore Hematology/Oncology - Manhasset
Manhasset, New York, United States
New York University School of Medicine
New York, New York, United States
Mount Sinai School of Medicine
New York, New York, United States
Fullerton Genetic
Asheville, North Carolina, United States
Duke Medical Center
Durham, North Carolina, United States
Akron Children's Hospital
Akron, Ohio, United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
University of Virginia Health Systems
Charlottesville, Virginia, United States
O & O Alpan, LLC
Springfield, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Pastores GM, Rosenbloom B, Weinreb N, Goker-Alpan O, Grabowski G, Cohn GM, Zahrieh D. A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability. Genet Med. 2014 May;16(5):359-66. doi: 10.1038/gim.2013.154. Epub 2013 Nov 21.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HGT-GCB-058
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.